H.C. Wainwright Reiterates Buy Rating on Kymera Therapeutics (KYMR)

April 10, 2026 6:44 AM

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $134.00 price target on Kymera Therapeutics (NASDAQ: KYMR).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found